Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL H JACOBS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1356323166
CMS profile
197134
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,641.47

237 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL H JACOBS

NPI 1356323166 · CMS profile ID 197134

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356323166?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL H JACOBS, NPI 1356323166, CMS profile ID 197134. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356323166?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DANIEL H JACOBS, NPI 1356323166, CMS profile ID 197134. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356323166?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DANIEL H JACOBS, NPI 1356323166, CMS profile ID 197134, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1356323166?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

237 matching records · $3,641.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 237 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–237 of 237.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $13.4402/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835899969 CMS
EMD Serono, Inc. $40.0002/19/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849215479 CMS
EMD Serono, Inc. $53.4502/19/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849215483 CMS
AstraZeneca Pharmaceuticals LP $13.4902/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829980701 CMS
Novartis Pharmaceuticals Corporation $12.7102/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812730339 CMS
Lilly USA, LLC $13.8002/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819035203 CMS
EMD Serono, Inc. $18.5702/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849162005 CMS
Eisai Inc. $14.9702/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817843281 CMS
Horizon Therapeutics plc $28.0202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797152657 CMS
Novartis Pharmaceuticals Corporation $4.3602/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812730337 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.4302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819990987 CMS
Acorda Therapeutics, Inc $18.1702/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792554275 CMS
GENZYME CORPORATION $17.5002/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843456617 CMS
Biogen, Inc. $11.3402/04/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827830565 CMS
Teva Pharmaceuticals USA, Inc. $2.5402/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839489677 CMS
Teva Pharmaceuticals USA, Inc. $11.5202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839489681 CMS
Allergan, Inc. $12.6402/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792818639 CMS
Novartis Pharmaceuticals Corporation $1.1502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812730335 CMS
AbbVie Inc. $16.0902/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794935255 CMS
Sunovion Pharmaceuticals Inc. $17.0702/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821752143 CMS
GENZYME CORPORATION $17.8801/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843456619 CMS
EMD Serono, Inc. $20.8801/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849162067 CMS
Biogen, Inc. $1.8201/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827830541 CMS
Biogen, Inc. $22.3701/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827830543 CMS
UCB, Inc. $20.6201/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807295127 CMS
Neurocrine Biosciences, Inc. $13.7801/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837797395 CMS
CATALYST PHARMACEUTICALS, INC. $24.5201/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828332539 CMS
Genentech USA, Inc. $17.6001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835899965 CMS
ACADIA Pharmaceuticals Inc $14.4201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838003773 CMS
Novartis Pharmaceuticals Corporation $16.8201/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812730341 CMS
UCB, Inc. $17.9701/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807307835 CMS
Teva Pharmaceuticals USA, Inc. $2.7901/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839489669 CMS
Teva Pharmaceuticals USA, Inc. $16.2501/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839489673 CMS
GENZYME CORPORATION $16.9401/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843456615 CMS
Novartis Pharmaceuticals Corporation $2.1301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812730333 CMS
Amneal Pharmaceuticals LLC $12.3601/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829661161 CMS
Lundbeck LLC $16.3001/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845914003 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,388.69 208
PY2020 $3,573.13 149
PY2021 $3,641.47 237
PY2022 $5,453.39 281
PY2023 $7,523.71 279
PY2024 $3,300.71 176
PY2025 $11,581.97 238

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $125,532.99 21
PY2024 Principal investigator $43,065.94 13
PY2023 Principal investigator $158,179.47 23
PY2022 Principal investigator $107,644.79 13
PY2021 Principal investigator $534,226.18 52
PY2020 Principal investigator $250,274.10 47
PY2019 Principal investigator $186,919.04 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $5,496.00 10/28/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627291
Principal investigator 1 Novartis Pharmaceuticals Corporation $182.01 10/28/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO, PA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307527
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,477.97 10/27/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO, PA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190307531
Principal investigator 1 Genentech, Inc. $19,563.00 09/17/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627287
Principal investigator 1 Genentech, Inc. $5,496.00 07/21/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627283
Principal investigator 1 F. Hoffmann-La Roche AG $30.00 07/02/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627251
Principal investigator 1 F. Hoffmann-La Roche AG $128.00 07/02/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627254
Principal investigator 1 F. Hoffmann-La Roche AG $64.00 07/02/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627257
Principal investigator 1 F. Hoffmann-La Roche AG $15.00 07/02/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627261
Principal investigator 1 Genentech, Inc. $2,150.00 06/10/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627266
Principal investigator 1 Genentech, Inc. $5,496.00 05/09/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627279
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,850.00 02/19/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO, PA
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307535
Principal investigator 1 Genentech, Inc. $5,496.00 02/14/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627271
Principal investigator 1 Genentech, Inc. $10,603.00 02/13/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211627275
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,910.08 01/31/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO, PA
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307529
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,275.00 01/30/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICE OF ORLANDO P
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190301281
Principal investigator 1 F. Hoffmann-La Roche AG $1,820.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627235
Principal investigator 1 F. Hoffmann-La Roche AG $278.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627239
Principal investigator 1 F. Hoffmann-La Roche AG $278.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627244
Principal investigator 1 F. Hoffmann-La Roche AG $3,044.00 01/22/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO PA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211627248
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,880.93 01/01/2025 Non-covered Recipient Entity
NEUROLOGICAL SERVICES OF ORLANDO, PA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190307533